Plain-English translation of NCT05010772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , given as a pill by mouth, can help prevent acute myeloid leukemia from coming back after you've achieved remission (when the cancer is no longer detectable). The study will test this medication alone or combined with one of four other drugs to see which approach is safest and most effective at keeping the disease from returning.
After leukemia goes into remission, there is still a risk that the disease could return. This medication has shown promise in treating leukemia, and researchers want to see if using it as a maintenance therapy—a long-term preventive treatment after initial therapy—can help keep patients in remission longer and improve their chances of survival.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth on specific days each month, repeating this cycle for up to 6 months or longer depending on which treatment arm you are assigned to. Some participants will receive the medication alone, while others will receive it combined with one of four additional drugs. You will have regular visits to monitor how well the treatment is working, check for side effects, and have blood tests done to track your leukemia status.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States